

List of Drugs for Rare Cancers in Hong Kong
香港罕見癌症藥物清單

Definition of Rare Cancers 罕見癌症定義

Incidence rate of less than 6 per 100,000 persons per year 每年每 10 萬人中發病率低於 6 例 (source 資料來源 : Rare Cancers Europe)

Incidence rate of less than 15 per 100,000 persons per year 每年每 10 萬人中發病率低於 15 例 (source 資料來源 : National Cancer Institute - USA)

Date Published 發佈日期 : 2025.05.05 (Updates are shown in blue 藍色字體為更新部分)

The information in this file is for reference only and not exhaustive. It is not intended to be a substitute for professional medical advice. Updated information will be published from time to time.
本文件資訊只供參考，並非詳盡無遺，亦不能取代醫生或其他合格醫療專業人員的建議。如有資料更新，將會不時發佈。

The content of the list is copyrighted by Rare Diseases Hong Kong (RDHK) and may not be reproduced, copied, downloaded or disseminated, in any way, for any commercial purpose, without prior written authorization and approval from RDHK. Individuals may print one hard copy for personal use, provided that content is unmodified and includes RDHK's copyright.

本清單內容為香港罕見病（RDHK）版權所有，事先未經RDHK書面授權和批准，不得以任何方式複製、複製、下載或傳播用於任何商業用途。個人使用可供複製或列印，惟內容未能修改且包含RDHK版權的部分。

The content of the list is copyrighted by Rare Diseases Hong Kong (RDHK) and may not be reproduced, copied, downloaded or disseminated, in any way, for any commercial purpose, without prior written authorization and approval from RDHK. Individuals may print one hard copy for personal use, provided that content is unmodified and includes RDHK's copyright.

No. 序	Ingredients 成分	Reference Indications 參考適應症	Cancer Types 癌症分類	Drug Formulary Category* 藥物名冊分類 *	Source of drug information 藥物資料來源
1	ABIRATERONE	For metastatic castration resistant prostate cancer (mCRPC) progressed on or after docetaxel-based chemotherapy regimen 適用於治療藥物或手術去勢抗性的轉移性前列腺癌，並且已使用過多西紫杉醇(Docetaxel)而治療無效者	Prostate cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
		For the treatment of adult men with metastatic castration resistant prostate cancer (mCRPC) who are unsuitable for Docetaxel treatment on the basis of predicted intolerance to Docetaxel 適用於治療成年男性藥物或手術去勢抗性的轉移性前列腺癌，而基於預期對多西紫杉醇(Docetaxel) 治療不耐受，患者不適合接受多西紫杉醇(Docetaxel)治療	Prostate cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
2	ACALABRUTINIB	Relapsed / refractory Chronic lymphocytic leukaemia (CLL) 復發或難治慢性淋巴細胞白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
		Previously untreated chronic lymphocytic leukaemia (CLL) with unmutated IGHV 慢性淋巴細胞白血病，而患者未曾接受任何治療及沒有 IGHV 突變			
		For adult patients with relapsed or refractory mantle cell lymphoma 用於治療患有復發或難治被套細胞淋巴瘤的成人患者	Lymphatic system cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
3	ACTINOMYCIN D	Chronic lymphocytic leukaemia (CLL) in adults	Blood and bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
		Ewing's sarcoma Wilm's tumour	Bone or soft tissue cancer Kidney cancer	General Drugs General Drugs	MIMS HK MIMS HK
4	ALECTINIB	ALK+ve non-small cell lung cancer (NSCLC) (first-line treatment) 間變性淋巴瘤激酶(ALK)呈陽性非小細胞肺癌（一線治療） ALK+ve metastatic non-small cell lung cancer (NSCLC), progressed on Crizotinib and intolerant to Ceritinib, or have CNS-progression after Crizotinib ALK 陽性的晚期非小細胞肺癌，患者接受克唑替尼治療中惡化而對塞瑞替尼不耐受，或曾接受過克唑替尼治療而出現中樞神經系統轉移	Lung cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
5	ALEMTUZUMAB	B cell chronic lymphocytic leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
6	ALPELISIB	In combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor positive, human epidermal growth factor receptor 2 negative, PIK3CA- mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen 與氟維司群結合使用作為治療具激素受體呈陽性、第二型人類表皮生長因子受體呈陰性、PIK3CA突變，及在接受內分泌基礎方案後仍出現病情惡化的晚期或轉移性乳癌的絕經後婦女及男性患者	Breast cancer	Self-financed item Without Safety Net	LegCo Website
7	APALUTAMIDE	Prostate cancer 前列腺癌	Prostate cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
8	ARSENIC TRIOXIDE	Acute promyelocytic leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
9	ASCIMINIB	Philadelphia chromosome positive CML in chronic phase (Ph+ CML-CP), in adults previously treated with >=2 tyrosine kinase inhibitors	Blood and bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
10	ASPARAGINASE	Acute lymphoblastic leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK

11	ATEZOLIZUMAB	For EGFR-ve and ALK-ve metastatic non-small cell lung cancer (NSCLC) progressed on or following platinum-based chemotherapy 用於患有 EGFR 基因變異陰性及 ALK-陰性轉移性非小細胞肺癌(NSCLC) 並曾接受含鉑化療而病情惡化的患者	Lung cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
12	ATEZOLIZUMAB	As monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression $\geq 50\%$ tumour cells (TC) and who do not have EGFR mutant or ALK-positive NSCLC 作為單一藥物治療，用於沒有 EGFR 基因變異或 ALK呈陽性的轉移性非小細胞肺癌 (NSCLC) 的成年患者之第一線治療，其腫瘤的 PD-L1 基因表達程度 $\geq 50\%$ In combination with carboplatin and etoposide for first-line treatment of adult patients with extensive-stage small cell lung cancer 與卡鉑和依托泊苷聯合用於成人廣泛期小細胞肺癌的一線治療	Lung cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
13	ATEZOLIZUMAB	Monotherapy as adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC at high risk of recurrence whose tumors have PD-L1 expression on $\geq 50\%$ of TC and do not have EGFR mutant or ALK positive NSCLC	Lung cancer	Self-financed item Without Safety Net	MIMS HK
14	ATEZOLIZUMAB AND BEVACIZUMAB	For the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. 適用於治療未曾接受全身系統性療程且晚期或無法切除的肝細胞癌(HCC)成年患者	Liver cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
15	AVELUMAB	Monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum-based chemotherapy 用於鉑類化療後沒有惡化的局部晚期或轉移性泌尿道上皮細胞癌的成人患者的一線單一維持治療	Bladder cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
16	AXITINIB	Advanced renal cell carcinoma (RCC)	Kidney cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
17	AZACITIDINE (ORAL)	Maintenance therapy in patients with acute myeloid leukemia (AML) in remission	Blood and bone marrow cancer	Self-financed item Without Safety Net	HA Website
18	AZACITIDINE (INJECTION)	Acute myeloid leukaemia (AML) 急性骨髓性白血病 Chronic myelomonocytic leukaemia (CMML) 慢性粒單細胞白血病 Myelodysplastic syndromes (MDS) 骨髓增生異常綜合症	Blood and bone marrow cancer	Special Drugs	HA Website
19	BELZUTIFAN	Von Hippel-Lindau (VHL) disease in adults who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery	Kidney cancer / Brain cancer / Neuroendocrine cancer	Self-financed item Without Safety Net	MIMS HK
20	BENDAMUSTINE	Chronic lymphocytic leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
21	BEVACIZUMAB	Glioblastoma	Brain cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	
		Cervical cancer	Cervical cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	
		First line treatment of RAS mutant metastatic colorectal cancer in combination with chemotherapy in adult patients indicated for intensive treatment OR First line treatment of RAS wild type metastatic colorectal cancer in combination with chemotherapy in adult patients indicated for intensive treatment who are unsuitable for or intolerant to Cetuximab / Panitumumab 作為第一線治療，配合化療用於需接受強化治療的 RAS突變型之轉移性大腸直腸癌成人患者 或 作為第一線治療，配合化療用於需接受強化治療的 RAS 野生型之轉移性大腸直腸癌成人患者，而患者不適合接受西妥昔單抗/帕木單抗治療或產生不耐受	Colorectal cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	
		With carboplatin and paclitaxel for front-line fallopian tube [fallopian tube cancers] / primary peritoneal cancer 與卡鉑和紫杉醇併用於晚期輸卵管癌和原發性腹膜癌的第一線治療	Epithelial ovarian / fallopian tube / primary peritoneal cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
22	BLEOMYCIN	Testicular tumours	Germ cell tumor	General Drugs	MIMS HK
23	BLINATUMOMAB	Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
24	BORTEZOMIB	Multiple myeloma	Bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
		Mantle cell Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK

25	BRENTUXIMAB VEDOTIN	For the treatment of adult patients with relapsed or refractory CD30+ Hodgkin Lymphoma (RR/HL): (i) following autologous stem cell transplant (ASCT), or (ii) following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option 用於成人患者，治療復發或難治性 CD30+型何傑金氏淋巴瘤(HL)，而患者： (i) 已接受自身幹細胞移植，或 (ii) 經歷最少兩類自身幹細胞移植或多項化療的療程均屬不合適的選項 For the treatment of adult patients with relapsed or refractory systemic anaplastic large cell Lymphoma 用於成人患者，治療復發或難治性全身間變性大型細胞淋巴瘤 For the treatment of adult patients with CD30+ cutaneous T-cell Lymphoma (CTCL) after at least 1 prior systemic therapy 用於成人患者，治療 CD30+皮膚型 T 細胞淋巴瘤，且先前至少已接受一種全身性治療	Bone marrow cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
26	BRENTUXIMAB VEDOTIN	Hodgkin's disease, Anaplastic large cell Lymphoma, CD-30 positive cutaneous T-cell Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
27	BRIGATINIB	ALK+ve non-small cell lung cancer (NSCLC) (first-line treatment) ALK呈陽性非小細胞肺癌 ALK+ve metastatic non-small cell lung cancer (NSCLC), progressed on Crizotinib and intolerant to Ceritinib, or have CNS-progression after Crizotinib 治療克唑替尼治療中惡化之ALK 陽性的晚期非小細胞肺癌患者，而患者需對塞瑞替尼不耐受或曾接受過克唑替尼治療而出現中樞神經系統轉移	Lung cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
28	BUSULPHAN	Chronic myeloid leukemia (CML)	Blood and bone marrow cancer	Special Drugs	MIMS HK
29	CABOZANTINIB (CABOMETYX)	Monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated w/ sorafenib.	Liver cancer	Self-financed item Without Safety Net	MIMS HK
30	CAPMATINIB	For the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping 用於治療有間質上皮轉化外顯子14跳躍突變的轉移性非小細胞肺癌的成年患者	Lung cancer	Self-financed item Without Safety Net	LegCo Website
31	CARBOPLATIN	Small cell lung cancer	Lung cancer	General Drugs	MIMS HK
32	CARFILZOMIB	Multiple myeloma	Bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
33	CARMUSTINE	Malignant glioma Recurrent glioblastoma multiforme Hodgkin's disease, Non-Hodgkin's Lymphoma	Brain and spinal cord cancer Brain cancer Lymphatic system cancer	General Drugs General Drugs General Drugs	MIMS HK MIMS HK MIMS HK
34	CERITINIB	ALK+ve non-small cell lung cancer (NSCLC) (first line treatment) ALK 呈陽性非小細胞肺癌 ALK+ve advanced non-small cell lung cancer (NSCLC) previously treated with Crizotinib 曾經接受克唑替尼療程，ALK 呈陽性晚期非小細胞肺癌的成年患者	Lung cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
35	CETUXIMAB	Locally advanced squamous cell carcinoma of the head and neck Metastatic squamous cell carcinoma of the head and neck Recurrent squamous cell carcinoma of the head and neck RAS wild-type colorectal cancer	Head and neck cancer Head and neck cancer Colorectal cancer	Special Drugs Self-financed item Without Safety Net Self-financed item With Safety Net (Samaritan Fund)	MIMS HK MIMS HK HA Website
36	CHLORAMBUCIL	Chronic lymphocytic leukaemia Hodgkin's disease, Non-Hodgkin's Lymphoma	Blood and bone marrow cancer Lymphatic system cancer	General Drugs General Drugs	MIMS HK MIMS HK
37	CISPLATIN	Metastatic testicular tumours	Germ cell tumor	General Drugs	MIMS HK
38	CLADRIBINE	B cell chronic lymphocytic leukaemia Hairy cell leukaemia Waldenstrom's macroglobulinaemia	Blood and bone marrow cancer Lymphatic system cancer	General Drugs Special Drugs	MIMS HK MIMS HK
39	CLADRIBINE (MAVENCLAD)	B cell chronic lymphocytic leukaemia Hairy cell leukaemia Waldenstrom's macroglobulinaemia	Blood and bone marrow cancer Lymphatic system cancer	Self-financed item With Safety Net (Samaritan Fund) Self-financed item With Safety Net (Samaritan Fund)	MIMS HK MIMS HK
40	CLOFARABINE	Acute lymphoblastic leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
41	CRISANTASPASE (ASPARAGINASE ERW)	Acute lymphoblastic leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
42	CRIZOTINIB	ALK+ve non-small cell lung cancer (NSCLC) ALK 呈陽性非小細胞肺癌 ROS1-positive non-small cell lung cancer (NSCLC) ROS1 呈陽性非小細胞肺癌	Lung cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website

43	CYCLOPHOSPHAMIDE	Acute lymphocytic leukaemia, Acute myeloid leukaemia, Chronic lymphocytic leukaemia, Chronic myeloid leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
		Advanced mycosis fungoides	Blood cancer	General Drugs	MIMS HK
		Multiple myeloma	Bone marrow cancer	General Drugs	MIMS HK
		Ewing's sarcoma	Bone or soft tissue cancer	General Drugs	MIMS HK
		Retinoblastoma	Eye cancer	General Drugs	MIMS HK
		Small cell lung cancer	Lung cancer	General Drugs	MIMS HK
		Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma	Lymphatic system cancer	General Drugs	MIMS HK
44	CYTARABINE	Leukaemic meningitis	Blood and bone marrow cancer	General Drugs	MIMS HK
45	DABRAFENIB	For the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma 用於成年患者以治療BRAF V600突變呈陽性而不能切除的或轉移性黑色素瘤	Skin cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
		For the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection 作為術後輔助治療，用於已完全切除腫瘤的 BRAF V600突變 III 期黑色素瘤成人患者			
46	DACARBAZINE	Soft tissue sarcoma	Bone or soft tissue cancer	General Drugs	MIMS HK
		Hodgkin's disease	Lymphatic system cancer	General Drugs	MIMS HK
		Metastatic melanoma	Skin cancer	General Drugs	MIMS HK
47	DARATUMUMAB	Multiple myeloma	Bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
48	DARATUMUMAB AND BORTEZOMIB	Systemic AL amyloidosis 全身性輕鏈類澱粉沉積症	Bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
		In combination with thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma (MM) who are eligible for autologous stem cell transplant 與沙利度胺和地塞米松併用，治療符合自體幹細胞移植條件的新診斷多發性骨髓瘤成年患者	Bone marrow cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
49	DARATUMUMAB AND LENALIDOMIDE	In combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy 與地塞米松併用，治療曾接受至少一種療法的多發性骨髓瘤成年患者	Bone marrow cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
50	DAROLUTAMIDE	In combination with docetaxel and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in adult men	Prostate cancer	Self-financed item Without Safety Net	MIMS HK
51	DASATINIB	Imatinib-resistant chronic myeloid leukaemia (CML) 對伊馬替尼(Imatinib)具抗藥性的慢性骨髓性白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
		Imatinib-resistant philadelphia or BCR/ABL positive acute lymphoblastic leukaemia (ALL) 對伊馬替尼(Imatinib)具抗藥性及伴有費城染色體的急性淋巴細胞白血病			
		Newly diagnosed chronic myeloid leukaemia (CML) in chronic phase 處於慢性期及新斷症的慢性骨髓性白血病			
		Nilotinib-resistant chronic myeloid leukaemia (CML) 對尼洛替尼(Nilotinib)具抗藥性的慢性骨髓性白血病			
52	DAUNORUBICIN	Chronic myeloid leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
		Acute leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
53	DINUTUXIMAB BETA	AIDS-related Kaposi's sarcoma	Endothelial cell cancer	General Drugs	MIMS HK
		Treatment of high-risk or relapse/refractory neuroblastoma 治療高風險或復發 / 難治的神經母細胞瘤	Brain cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
54	DOCETAXEL	Head and neck cancer	Head and neck cancer	Special Drugs	MIMS HK
		Head and neck cancer	Head and neck cancer	Self-financed item Without Safety Net	MIMS HK
55	DOSTARLIMAB	As monotherapy for the treatment of adult patients with mismatch repair deficient/microsatellite instability-high recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen. 用作單一治療在接受含鉑療法期間或治療後出現病情惡化之復發性或晚期錯配修復缺陷或微衛星體不穩定性高的子宮內膜癌的成年患者 In combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy	Endometrial cancer	Self-financed item Without Safety Net	MIMS HK / LegCo Website
56	DOXORUBICIN	Acute leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
		Osteosarcoma	Bone cancer	General Drugs	MIMS HK
		Advanced Soft tissue sarcoma	Bone or soft tissue cancer	General Drugs	MIMS HK
		Wilm's tumour	Kidney cancer	General Drugs	MIMS HK

57	DOXORUBICIN (LIPOSOMAL)	Hodgkin's Lymphoma	Lymphatic system cancer	General Drugs	MIMS HK
		Acute leukaemia	Blood and bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
		Osteosarcoma	Bone cancer	Self-financed item Without Safety Net	MIMS HK
		Multiple myeloma	Bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
		Advanced Soft tissue sarcoma	Bone or soft tissue cancer	Self-financed item Without Safety Net	MIMS HK
		AIDS-related Kaposi's sarcoma	Endothelial cell cancer	Self-financed item Without Safety Net	MIMS HK
		Wilm's tumour	Kidney cancer	Self-financed item Without Safety Net	MIMS HK
		Hodgkin's Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
		Non-Hodgkin's Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
		Second-line of platinum refractory or subsequent treatment of platinum resistant advanced ovarian cancer 鉑化合物無效後的第二線或後續鉑化合物抗藥的卵巢癌治療	Ovarian cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	MIMS HK
58	DURVALUMAB	Unresectable and stage III non-small cell lung cancer (NSCLC) not progressed following concurrent platinum-based chemotherapy and radiation therapy 適用於患有無法以手術切除的第三期非小細胞肺癌，並接受放射治療合併含鉑化療後病情未惡化的病人	Lung cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
59	ENCORAFENIB AND CETUXIMAB	For the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, who have received prior systemic therapy 作為治療患有BRAF V600E突變的轉移性大腸癌的成年患者，而該患者先前已接受過全身系統性療程	Colorectal cancer	Self-financed item Without Safety Net	LegCo Website
60	ENFORTUMAB VEDOTIN	Monotherapy for locally advanced or metastatic urothelial cancer in adult who have previously received a platinum-containing chemotherapy and a PD-1 or PD-L1 inhibitor	Bladder cancer	Self-financed item Without Safety Net	MIMS HK
61	ENZALUTAMIDE	For metastatic castration resistant prostate cancer (mCRPC) progressed on or after docetaxel-based chemotherapy regimen 適用於治療藥物或手術去勢抗性的轉移性前列腺癌，並且已使用過多西紫杉醇(Docetaxel)而治療無效者	Prostate cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
		For the treatment of adult men with metastatic castration resistant prostate cancer (mCRPC) who are unsuitable for Docetaxel treatment on the basis of predicted intolerance to Docetaxel 適用於治療成年男性藥物或手術去勢抗性的轉移性前列腺癌，而基於預期對多西紫杉醇(Docetaxel)治療不耐受，患者不適合接受多西紫杉醇(Docetaxel)治療			
		Metastatic Hormone-Sensitive Prostate Cancer	Prostate cancer	Self-financed item Without Safety Net	HA Website
62	EPIRUBICIN	Acute leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
		Multiple myeloma	Bone marrow cancer	General Drugs	MIMS HK
63	ERIBULIN	Treatment of adult patients with unresectable liposarcoma who have received prior anthracycline-containing therapy (unless unsuitable) for advanced or metastatic disease	Bone or soft tissue cancer	Special Drugs	MIMS HK
64	ERLOTINIB	Metastatic pancreatic cancer	Pancreatic cancer	Special Drugs	MIMS HK
65	ETOPOSIDE	Testicular cancer	Germ cell tumor	General Drugs	MIMS HK
		Small cell lung cancer	Lung cancer	General Drugs	MIMS HK
66	EVEROLIMUS (AFINITOR)	For HR+ve HER2-ve advanced breast cancer, in combination with Exemestane, in postmenopausal women with bone-only disease after recurrence or progression following a non-steroidal aromatase inhibitor. 與依西美坦 (Exemestane) 併用，治療停經後的晚期荷爾蒙接受體陽性、HER2 受體陰性骨轉移乳癌，患者先前已使用過非類固醇類之芳香環酶抑制劑治療無效	Breast cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	MIMS HK
		Neuroendocrine tumours of gastrointestinal origin	Neuroendocrine cancer	Self-financed item Without Safety Net	MIMS HK
		Neuroendocrine tumours of lung origin			
		Unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic origin in adults w/ progressive disease			
		Renal cell carcinoma	Kidney cancer	Self-financed item Without Safety Net	MIMS HK
67	FLUDARABINE	B cell chronic lymphocytic leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
68	FLUOROURACIL	Pancreatic carcinoma	Pancreatic cancer	General Drugs	MIMS HK
		Superficial basal cell carcinoma			
69	GEMCITABINE	Cancer, pancreatic	Pancreatic cancer	General Drugs	MIMS HK

70	GEMTUZUMAB OZOGAMICIN	In combination with daunorubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukaemia (AML), except acute promyelocytic leukaemia (APL) 與柔紅霉素及阿糖胞苷合使用，用作治療 15 歲及以上患有原發性 CD33 型呈陽性的急性骨髓性白血病(急性早幼骨髓性白血病除外)，而之前未曾接受治療的患者	Blood and bone marrow cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
71	GILTERITINIB	Relapsed or refractory acute myeloid leukaemia (AML) 復發性或難治性急性骨髓性白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
72	HYDROXYUREA	chronic myelogenous leukemia	Blood and bone marrow cancer	General Drugs	MIMS HK
73	IBRUTINIB	Relapsed or refractory mantle cell Lymphoma (MCL) 復發或難治性套細胞淋巴瘤 Chronic lymphocytic leukaemia (CLL) 慢性淋巴細胞白血病 As a single agent or in combination with rituximab for the treatment of adult patients with Waldenström's macroglobulinaemia (WM) with MYD88 gene mutation who have received at least one prior therapy 單獨使用或與利妥昔單抗併用，治療曾接受至少一種治療並帶有 MYD88 基因突變的華氏巨球蛋白血症成人患者 As monotherapy for the treatment of adult patients with previously untreated Chronic Lymphocytic Leukaemia (CLL) without del17p or TP53 gene AND (1) CIRS>6; or (2) CrCl<70 mL/min; or (3) unsuitable for full dose fludarabine or bendamustine based therapies 作為單藥用於治療之前未接受治療的成年慢性淋巴細胞白血病 (CLL) 患者，且不具備 del17p 或 TP53 基因突變，及 (1) 累積疾病評分量表(CIRS) > 6; 或 (2) 肌酸酐清除率 (CrCl) < 70 mL/min; 或 (3) 不適合全劑量以氟達拉濱或苯達莫司汀為基礎的療法	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
74	IDARUBICIN	Acute myeloid leukaemia Acute lymphoblastic leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
75	IFOSFAMIDE	Germ cell testicular carcinoma	Testicular cancer	Special Drugs	MIMS HK
76	IMATINIB	Accelerated phase Philadelphia chromosome positive chronic myelogenous leukaemia, Blast phase Philadelphia chromosome positive chronic myelogenous leukaemia Chronic phase Philadelphia chromosome positive chronic myelogenous leukaemia Philadelphia chromosome-positive acute lymphoblastic leukaemia Myelodysplastic/myeloproliferative disease Dermatofibrosarcoma protuberans Gastrointestinal stromal tumour 胃腸道間質瘤 Dermatofibrosarcoma protuberans	Blood and bone marrow cancer Gastrointestinal cancer Skin cancer	Special Drugs Self-financed item With Safety Net (Samaritan Fund) Special Drugs	MIMS HK HA Website MIMS HK
77	INOTUZUMAB OZOGAMICIN	As monotherapy for the treatment of transplant-eligible adult patients with relapsed or refractory CD22-positive B cell acute lymphoblastic leukaemia (ALL) that is either Philadelphia chromosome negative, or Philadelphia chromosome positive failing at least 1 prior TKI treatment 作為單一使用的藥物，用於治療適合移植的復發或難治性 CD22 陽性 B 細胞急性淋巴細胞白血病的成年患者，並為費城染色體陰性或費城染色體陽性而之前使用過至少一種酪氨酸激酶抑制劑(TKI)治療無效	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
78	IRINOTECAN	Metastatic adenocarcinoma of pancreas	Pancreatic cancer	General Drugs	MIMS HK
79	ISATUXIMAB AND POMALIDOMIDE	In combination with dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy 與泊地塞米松聯合使用，作為治療患有復發性或難治性的多發性骨髓瘤的成年患者，而這些患者先前已接受過包括來那度胺及蛋白酶體抑制劑的至少兩種療法，並在最後療程出現病情惡化	Bone marrow cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
80	IXAZOMIB	In combination with dexamethasone for the treatment of multiple myeloma in patients who have received at least one prior therapy 與地塞米松組合使用，用於治療曾接受最少一次先前療程的多發性骨髓瘤患者	Bone marrow cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
81	LANREOTIDE	Carcinoid syndrome	Neuroendocrine cancer	Special Drugs	MIMS HK
82	LENALIDOMIDE	Myelodysplastic syndrome Multiple myeloma (MM) 多發性骨髓瘤 In combination with dexamethasone for the treatment of multiple myeloma in patients who have received at least one prior therapy 與地塞米松組合使用，用於治療曾接受最少一次先前療程的多發性骨髓瘤患者	Blood and bone marrow cancer Bone marrow cancer	Self-financed item Without Safety Net Self-financed item With Safety Net (Samaritan Fund) Self-financed item With Safety Net (CCF Medical Assistance Programmes)	MIMS HK HA Website

		Mantle cell Lymphoma, Follicular Lymphoma, Marginal zone Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
83	LENVATINIB	Unresectable hepatocellular carcinoma (HCC) 無法以手術切除腫瘤的肝癌	Liver cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
		Treatment of adult patients with progressive, locally advanced or metastatic, differentiated thyroid carcinoma (papillary/follicular/poorly differentiated/oncocyctic carcinoma), refractory to radioactive iodine 進展性、局部晚期或轉移性、放射性碘難治性分化型甲狀腺癌成人患者的治療	Thyroid cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
84	LENVATINIB AND PEMBROLIZUMAB	Treatment of patients with advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR), as determined by a validated test, or not microsatellite instability-high (MSI-H), who have disease progression following prior platinum-based chemotherapy in any setting and are not candidates for curative surgery or radiation 治療經驗證測試確定錯配修復良好(pMMR)或不具有微衛星不穩定性 (MSI-H)之晚期子宮內膜癌患者，這些患者須曾經接受過鉑類化療後疾病惡化和不適合進行根治手術或放射治療	Endometrial cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
		Lenvatinib in combination with pembrolizumab, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC)	Kidney cancer	Self-financed item Without Safety Net	MIMS HK
85	LOMUSTINE	Lung cancer	Lung cancer	General Drugs	MIMS HK
		Hodgkin's Lymphoma	Lymphatic system cancer	General Drugs	MIMS HK
		Metastatic malignant melanoma	Skin cancer	General Drugs	MIMS HK
86	LORLATINIB	Metastatic non-small cell lung cancer (NSCLC) whose tumors are ALK-positive and with baseline brain metastasis 用於治療患有間變性淋巴瘤激酶呈陽性，及基線存在腦轉移的轉移性非小細胞肺癌	Lung cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
		For the treatment of patients with ALK-positive metastatic NSCLC whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or alectinib or ceritinib or brigatinib as the first ALK inhibitor therapy for metastatic disease 用於治療患有間變性淋巴瘤激酶呈陽性，轉移性非小細胞肺癌，而且曾於接受以下的療程後仍出現病情惡化的成年患者： • 克唑替尼和至少另外一種間變性淋巴瘤激酶抑制劑作轉移性疾病的治療；或 • 阿來替尼或塞瑞替尼作或布格替尼為第一種間變性淋巴瘤激酶抑制劑作轉移性疾病的治療	Lung cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
87	LUTETIUM 177 VIPIVOTIDE TETRAXETAN	In combination with androgen deprivation therapy with or without androgen receptor (AR) pathway inhibition for adult patients with progressive PSMA-positive mCRPC who have been treated with AR pathway inhibition and taxane-based chemotherapy	Prostate cancer	Self-financed item Without Safety Net	LegCo Website
88	LUTETIUM OXODOTREOTIDE	For the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours in adults 用於治療不可切除或轉移性、漸進性、高度分化（G1及G2）生長抑素受體呈陽性的胃腸胰神經內分泌腫瘤的成年患者	Neuroendocrine cancer	Self-financed item Without Safety Net	LegCo Website
89	MELPHALAN	Acute lymphoblastic leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
		Trophoblastic neoplasm	Gestational trophoblastic cancer	General Drugs	MIMS HK
		Burkitt's Lymphoma	Lymphatic system cancer	General Drugs	MIMS HK
		Choriocarcinoma	Trophoblastic cancer	General Drugs	MIMS HK
90	MERCAPTOPURINE	Acute lymphoblastic leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
91	METHOTREXATE	Acute lymphoblastic leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
		Trophoblastic neoplasm	Gestational trophoblastic cancer	General Drugs	MIMS HK
		Burkitt's Lymphoma	Lymphatic system cancer	General Drugs	MIMS HK
		Choriocarcinoma	Trophoblastic cancer	General Drugs	MIMS HK
92	MIDOSTAURIN	Acute myeloid leukaemia (AML) 急性骨髓性白血病 Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM-AHN), or mast cell leukaemia (MCL) 侵襲性全身性肥大細胞增多症、全身性肥大細胞增多症伴相關血液腫瘤或肥大細胞白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
93	MITOMYCIN	Superficial bladder tumours	Bladder cancer	General Drugs	MIMS HK
		Head and neck cancer	Head and neck cancer	General Drugs	MIMS HK
		Pancreatic cancer	Pancreatic cancer	General Drugs	MIMS HK
94	MITOXANTRONE	Blast crisis in chronic myeloid leukaemia, Acute myeloid leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
		Non-Hodgkin's Lymphoma	Lymphatic system cancer	Special Drugs	MIMS HK

95	NILOTINIB	Dasatinib-resistant chronic myeloid leukaemia (CML) 對達沙替尼(Dasatinib) 具抗藥性的慢性骨髓性白血病 Imatinib-resistant chronic myeloid leukaemia (CML) 對伊馬替尼(Imatinib) 具抗藥性的慢性骨髓性白血病 Newly diagnosed chronic myeloid leukaemia (CML) in chronic phase 處於慢性期及新斷症的慢性骨髓性白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
96	NIRAPARIB (TOSYLATE)	Fallopian tube cancer	Fallopian tube cancer	Self-financed item Without Safety Net	MIMS HK
		primary peritoneal cancer	Peritoneal cancer	Self-financed item Without Safety Net	MIMS HK
97	NIRAPARIB (ZEJULA)	Ovarian cancer	Ovarian cancer	Self-financed item Without Safety Net	HA Website
98	NIVOLUMAB	Metastatic urothelial carcinoma	Bladder cancer	Self-financed item Without Safety Net	MIMS HK
		In combination with fluoropyrimidine- and platinum-based combination chemotherapy for the 1st line treatment of adult patients with human epidermal growth factor receptor 2 negative (HER2-ve) advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma whose tumours express PD-L1 with CPS>=5 聯合氟嘧啶和含鉑組合化療作為第一線治療，用於 HER2 陰性之晚期或轉移性胃腺癌、胃食管交界處腺癌或食道腺癌的成年患者，而腫瘤須呈 PD-L1 陽性 (綜合陽性分數>=5)	Gastrointestinal cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
		In combination with fluoropyrimidine-and platinum-containing chemotherapy, for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma whose tumors express CPS>=10 配合氟嘧啶和含鉑化療作為第一線治療，用於無法以手術切除之晚期或轉移性鱗狀上皮食道癌的成年患者，而腫瘤須呈PD-L1 綜合陽性分數>=10	Gastrointestinal cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
		For the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after platinum based therapy 治療接受含鉑化學治療時或之後疾病惡化的復發或轉移性頭頸部鱗狀細胞癌(SCCHN)病人	Head and neck cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
		Recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after platinum based therapy 治療接受含鉑化學治療時或之後疾病惡化的復發或轉移性頭頸部鱗狀細胞癌病人	Head and neck cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
		Metastatic squamous cell carcinoma of the head and neck	Head and neck cancer	Self-financed item Without Safety Net	MIMS HK
		Hepatocellular carcinoma	Liver cancer	Self-financed item Without Safety Net	MIMS HK
		EGFR-ve and ALK-ve metastatic non-small cell lung cancer (NSCLC) progressed on or following platinum-based chemotherapy 用於患有 EGFR 基因變異陰性及 ALK-陰性轉移性非小細胞肺癌(NSCLC) 並曾接受含鉑化療而病情惡化的患者	Lung cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
		Refractory classical Hodgkin Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
		Unresectable or metastatic melanoma 不可切除或轉移性黑色素瘤 For adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection 作為輔助性治療，用於腫瘤已擴散至淋巴結或其他部位，並已完全切除腫瘤的黑色素瘤患者	Skin cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
		Metastatic melanoma	Skin cancer	Self-financed item Without Safety Net	MIMS HK
99	NIVOLUMAB AND IPILIMUMAB	Unresectable malignant pleural mesothelioma (first-line treatment) 無法切除的惡性胸膜間皮瘤 (一線治療)	Mesothelioma	Self-financed item With Safety Net (Samaritan Fund)	HA Website
		Intermediate or poor risk advanced renal cell carcinoma (first-line treatment) 中度或高風險的晚期腎細胞癌 (一線治療)	Kidney cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
		In combination with 2 cycles of platinum double chemotherapy for first-line treatment of adult patients with metastatic or recurrent squamous NSCLC with no EGFR or ALK genomic tumor aberrations 聯合兩個週期的鉑類雙藥化療，用於沒有表皮生長因子受體(EGFR)或間變性淋巴瘤激酶(ALK)基因突變的轉移性或復發鱗狀非小細胞肺癌的成年患者，作一線治療	Lung cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
100	OBINUTUZUMAB	In combination with Chlorambucil for treatment of previously untreated Chronic lymphocytic leukaemia (CLL) in adult patients with comorbidities making them unsuitable for full-dose Fludarabine or Bendamustine based therapy 適用於與苯丁酸氮芥(Chlorambucil)併用，治療先前未曾接受過治療，且具有合併症而不適合接受全劑量含氟達拉濱(Fludarabine)或苯達莫司汀(Bendamustine)治療的慢性淋巴細胞白血病患者	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund & CCF Medical Assistance Programmes)	HA Website

		Chronic lymphocytic leukaemia	Blood and bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
		Follicular Lymphoma 濾泡性淋巴瘤	Lymphatic system cancer	Self-financed item With Safety Net (Samaritan Fund & CCF Medical Assistance Programmes)	HA Website
		Refractory follicular Lymphoma, Relapsed follicular Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
101	OCTREOTIDE	Severe secretory diarrhoea associated with vasoactive intestinal peptide-secreting tumour Diarrhoea associated with carcinoid tumour Flushing associated with carcinoid tumour Necrolytic migratory erythema associated with glucagonoma	Neuroendocrine cancer	General Drugs	MIMS HK
102	OLAPARIB	Monotherapy or in combination with endocrine therapy for the adjuvant treatment of adults with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy As maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian cancer who are in complete or partial response after first-line platinum based chemotherapy. (FIGO III-IV 期) 高分化晚期上皮性卵巢癌患者 · 有 BRCA 1/2 基因突變 (生殖細胞及 / 或體細胞突變) 而完成一線鉑類化療療程後有完全或部分緩解的維持治療 Metastatic castration-resistant prostate cancer (mCRPC) 轉移性去勢療法無效前列腺癌	Pancreatic cancer Breast cancer Fallopian tube cancer / Ovarian cancer / Peritoneal cancer Prostate cancer	General Drugs Self-financed item Without Safety Net Self-financed item With Safety Net (CCF Medical Assistance Programmes) Self-financed item Without Safety Net	MIMS HK MIMS HK HA Website HA Website
103	PACLITAXEL	HER2-overexpressing advanced or metastatic breast cancer AIDS-related Kaposi's sarcoma Metastatic adenocarcinoma of pancreas	Breast cancer Endothelial cell cancer Pancreatic cancer	General Drugs General Drugs General Drugs	MIMS HK MIMS HK MIMS HK
104	PACLITAXEL (ALBUMIN)	HER2-overexpressing advanced or metastatic breast cancer AIDS-related Kaposi's sarcoma Pancreatic cancer 胰臟癌	Breast cancer Endothelial cell cancer Pancreatic cancer	Self-financed item Without Safety Net Self-financed item Without Safety Net Self-financed item With Safety Net (Samaritan Fund)	MIMS HK MIMS HK HA Website
105	PAZOPANIB	Advanced soft tissue sarcoma	Bone or soft tissue cancer	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
106	PEGASPARAGINASE	Acute lymphoblastic leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
107	PEMBROLIZUMAB	First-line treatment for metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression with no EGFR or ALK genomic tumor aberrations 用於PD-L1水平高, 且沒有表皮生長因子受體(EGFR)或間變性淋巴瘤激酶(ALK)基因突變的轉移性非小細胞肺癌, 作一線治療 Metastatic urothelial carcinoma Treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy 治療局部晚期或轉移性泌尿道上皮癌 · 用於在接受鉑類組合化療期間或之後出現病情惡化 · 或於十二個月內接受過鉑類組合化療作為術前或術後治療的患者 Triple-negative breast cancer PD-L1 expression in metastatic cervical cancer PD-L1 expression in recurrent cervical cancer Metastatic microsatellite instability-high colorectal cancer PD-L1 expression in metastatic gastroesophageal junction adenocarcinoma PD-L1 expression in recurrent locally advanced gastroesophageal junction adenocarcinoma PD-L1 expression in metastatic squamous cell carcinoma of the head and neck PD-L1 expression in unresectable recurrent squamous cell carcinoma of the head and neck Metastatic squamous cell carcinoma of the head and neck Recurrent squamous cell carcinoma of the head and neck In combination with platinum and fluorouracil (FU) for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (CPS ≥1) as determined by a validated test 與含鉑化療藥物及氟尿嘧啶合併使用作為第一線治療已經擴散, 或復發並無法以手術切除的頭頸部鱗狀細胞癌, 患者腫瘤“PD-L1”測試結果須呈陽性 (CPS ≥1) Adjuvant treatment of patients with renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions	Blood and bone marrow cancer Bladder cancer Bladder cancer Breast cancer Cervical cancer Colorectal cancer Esophagus cancer Head and neck cancer Head and neck cancer Kidney cancer	Self-financed item With Safety Net (Samaritan Fund) Self-financed item Without Safety Net Self-financed item With Safety Net (CCF Medical Assistance Programmes) Self-financed item Without Safety Net Self-financed item Without Safety Net Self-financed item Without Safety Net Self-financed item Without Safety Net Self-financed item Without Safety Net Self-financed item With Safety Net (CCF Medical Assistance Programmes) Self-financed item Without Safety Net	HA Website MIMS HK HA Website HA Website MIMS HK MIMS HK MIMS HK MIMS HK HA Website MIMS HK

		First-line treatment for metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression with no EGFR or ALK genomic tumor aberrations 用於PD-L1水平高，且沒有表皮生長因子受體(EGFR)或間變性淋巴瘤激酶(ALK)基因突變的轉移性非小細胞肺癌，作一線治療	Lung cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
		In combination with carboplatin and paclitaxel for first-line treatment of adult patients with metastatic squamous NSCLC with PD-L1 expression (Tumor Proportion Score 1-49%) and no EGFR or ALK genomic tumor aberrations 聯合卡铂和紫杉醇類化療，用於沒有表皮生長因子受體(EGFR)或間變性淋巴瘤激酶(ALK)基因突變的轉移性鱗狀非小細胞肺癌的成年患者而其 PD-L1 水平腫瘤比例評分為 1-49%，作一線治療 In combination with pemetrexed and platinum chemotherapy for first-line treatment of metastatic nonsquamous NSCLC with PD-L1 expression (Tumor Proportion Score 1-49%) with no EGFR or ALK genomic tumor aberrations 聯合培美曲塞及含铂化療，用於沒有表皮生長因子受體(EGFR)或間變性淋巴瘤激酶(ALK)基因突變的轉移性非鱗狀非小細胞肺癌的患者，而其 PD-L1 水平腫瘤比例評分為 1-49%，作一線治療 In combination with pemetrexed and platinum chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC) with unknown or no PD-L1 expression with no EGFR or ALK genomic tumor aberrations 聯合培美曲塞及铂類化療，用於沒有表皮生長因子受體(EGFR)或間變性淋巴瘤激酶(ALK)基因突變的轉移性非鱗狀非小細胞肺癌的患者，且未知或沒有PD-L1表達的一線治療	Lung cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
		As monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin Lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) and Brentuximab Vedotin (BV), or who are transplant-ineligible and have failed BV 單一治療用於成人患者，治療復發或難治性典型何傑金氏淋巴瘤(cHL)，而患者已曾接受自身幹細胞移植(ASCT)及維布妥昔單抗(BV)治療但失敗，或不合適自身幹細胞移植及曾接受維布妥昔單抗(BV)治療但失敗 As monotherapy for the treatment of paediatric patients aged 3 years and older with relapsed or refractory cHL who have failed ASCT or following at least two prior therapies when ASCT is not a treatment option 單一治療用於三歲或以上的兒童患者，治療復發或難治性典型何傑金氏淋巴瘤(cHL)，而患者曾接受自體幹細胞移植(ASCT)治療但無效，或無法接受自體幹細胞移植治療且曾接受至少兩種其他治	Lymphatic system cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
		Refractory classical Hodgkin Lymphoma, Relapsed classical Hodgkin Lymphoma, Primary mediastinal large B-cell Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
		Metastatic melanoma	Skin cancer	Self-financed item Without Safety Net	MIMS HK
108	PEMETREXED	Malignant pleural mesothelioma	Lung cancer	Special Drugs	MIMS HK
109	PLERIXAFOR	Multiple myeloma (MM) 多發性骨髓瘤 Non-Hodgkin's Lymphoma (NHL) 非何傑金氏淋巴瘤	Bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
			Lymphatic system cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
110	POLATUZUMAB VEDOTIN AND RITUXIMAB	In combination with cyclophosphamide, doxorubicin, and prednisone /prednisolone for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL) and have International Prognostic Index (IPI) score 3-5 結合環磷酰胺、阿黴素和普羅松，用於先前未曾接受治療的瀰漫性大 B 細胞淋巴瘤成年患者，而其國際預後指數(IPI)為3-5 Previously untreated diffuse large B-cell lymphoma (DLBCL)	Lymphatic system cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
			Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
111	POLATUZUMAB VEDOTIN, RITUXIMAB AND BENDAMUSTINE	For the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant 用於治療復發性/難治性瀰漫性大 B 細胞淋巴瘤 (DLBCL)，而不適合進行造血幹細胞移植的成人患者	Lymphatic system cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
112	POMALIDOMIDE	Multiple myeloma (MM) 多發性骨髓瘤	Bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
113	PONATINIB	Acute lymphoblastic leukaemia (ALL) 急性淋巴細胞白血病 Chronic myeloid leukaemia (CML) 慢性骨髓性白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
114	PROCARBAZINE	Hodgkin's disease	Lymphatic system cancer	General Drugs	MIMS HK
115	REGORAFENIB	Unresectable, metastatic malignant gastrointestinal stromal tumours	Gastrointestinal cancer	Self-financed item Without Safety Net	MIMS HK

116	RITUXIMAB	Maintenance therapy for relapsed follicular Lymphoma (RFL) 復發濾泡性淋巴瘤的維持性治療	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website MIMS HK
		Previously-untreated and relapsed / refractory Chronic lymphocytic leukaemia (CLL) 從未治療及復發 / 難治慢性淋巴細胞白血病			
		CD20 positive diffuse large B-cell Lymphoma 瀰漫性大型 B 細胞非何杰金氏淋巴瘤			
		CD20 positive diffuse Burkitt Lymphoma 瀰漫性伯基特淋巴瘤			
		Refractory follicular Lymphoma Relapsed follicular Lymphoma Chronic lymphocytic leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
		Refractory follicular Lymphoma Relapsed follicular Lymphoma CD20-positive diffuse large B cell Non-Hodgkin's Lymphoma CD20-positive non-progressing low-grade Non-Hodgkin's Lymphoma Advanced follicular Non-Hodgkin's Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
117	SACITUZUMB GOVITECAN	Treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more prior systemic therapies, at least one of them for metastatic disease	Breast cancer	Self-financed item Without Safety Net	MIMS HK
118	SELINEXOR	In combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy 與地塞米松結合使用，用於治療已接受過至少四種療法且其疾病對至少兩種蛋白酶體抑制劑、兩種免疫調節劑和一種抗CD38單克隆抗體難治並在最後一種療法時病情惡化的多發性骨髓瘤成人患者	Bone marrow cancer	Self-financed item Without Safety Net	LegCo Website
119	SELUMETINIB	For the treatment of symptomatic, inoperable plexiform neurofibromas (PN) actively progressing on imaging in paediatric patients with neurofibromatosis type 1 (NF1) aged 3 to 18 years 用於治療 3 至 18 歲患有神經纖維瘤病一型的兒童患者，患者臨床症狀明顯、手術無法清除、並從影像學上顯示增長中的叢狀神經纖維瘤	Brain cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
		for the treatment of paediatric patients 2 years of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas 用於治療患有神經纖維瘤病一型，並且出現有症狀、手術無法清除的叢狀神經纖維瘤的兩歲及以上的兒童患者	Brain cancer	Self-financed item Without Safety Net	LegCo Website
120	SORAFENIB	Hepatocellular carcinoma (HCC) 肝細胞癌	Liver cancer	Special Drugs	HA Website
121	SUNITINIB	Gastrointestinal tumour 腸胃癌	Gastrointestinal cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
		Advanced Renal Cell Carcinoma (RCC)	Kidney cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	MIMS HK
		Advanced Pancreatic Neuroendocrine Tumors (pNET)	Pancreatic cancer	Self-financed item Without Safety Net	MIMS HK
122	TEMOZOLOMIDE	Glioblastoma multiforme, Refractory anaplastic astrocytoma, Anaplastic astrocytoma, Recurrent glioblastoma multiforme	Brain cancer	Special Drugs	MIMS HK
		Recurrent high grade glioma 復發的惡性神經膠質瘤	Brain cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
123	TEPOTINIB	For the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations 用於治療有間質上皮轉化外顯子14跳躍改變的轉移性非小細胞肺癌的成年患者	Lung cancer	Self-financed item Without Safety Net	LegCo Website
124	THALIDOMIDE	Multiple myeloma	Bone marrow cancer	General Drugs	MIMS HK
125	THIOGUANINE	Acute lymphoblastic leukaemia, Acute myeloid leukaemia, Chronic myeloid leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
126	TISAGENLECLEUCEL	Paediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukaemia that is refractory, in relapse post-transplant or in second or later relapse 用於治療年齡為25歲或以下的復發或難治性B細胞急性淋巴母細胞性白血病患者 Adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy 兩種或以上全身系統性療程後復發或難治性的瀰漫性大型B細胞淋巴瘤的成年患者 For the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy 用於治療兩種或以上全身系統性療程後復發或難治性的 濾泡性淋巴瘤的成年患者	Blood and bone marrow cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website

127	TOPOTECAN	Cervical cancer	Cervical cancer	Self-financed item Without Safety Net	MIMS HK
		Small cell lung cancer	Lung cancer	Self-financed item Without Safety Net	MIMS HK
128	TRAMETINIB	For the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma 用於成年患者以治療BRAF V600突變呈陽性而不能切除的或轉移性黑色素瘤 For the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection 作為術後輔助治療，用於已完全切除腫瘤的 BRAF V600突變 III 期黑色素瘤成人患者	Skin cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
129	TRASTUZUMAB DERUXTECAN	As monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one prior anti-HER2-based regimen 作為單藥治療，用於治療人類表皮生長因子受體2(HER2)呈陽性之不可切除或轉移性乳癌的成人患者，而患者曾接受一種的其他專門針對HER2 陽性乳癌的治療方法	Breast cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
		Monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy	Breast cancer	Self-financed item Without Safety Net	MIMS HK
130	TRETINOIN	Acute promyelocytic leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
131	TRIFLURIDINE AND TIPIRACIL	For the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy	Gastrointestinal cancer	Self-financed item Without Safety Net	HA Website, MIMS HK
132	VEMURAFENIB	As monotherapy for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma 用於成年病人以治療 BRAF V600 突變呈陽性而不能切除的或轉移性黑色素瘤的單一療法	Skin cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
133	VENETOCLAX	Newly diagnosed acute myeloid leukaemia (AML) 新確診的急性髓性白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
		Chronic lymphocytic leukaemia, Small lymphocytic Lymphoma	Blood and bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
134	VINBLASTINE	Advanced mycosis fungoides	Blood cancer	General Drugs	MIMS HK
		Kaposi's sarcoma	Endothelial cell cancer	General Drugs	MIMS HK
		Testicular cancer	Germ cell tumor	General Drugs	MIMS HK
		Langerhans cell histiocytosis	Histiocytes cancer	General Drugs	MIMS HK
		Hodgkin's disease, Lymphocytic Lymphoma	Lymphatic system cancer	General Drugs	MIMS HK
		Acute lymphoblastic leukaemia, Acute myeloid leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
		Wilm's tumour	Kidney cancer	General Drugs	MIMS HK
		Small cell lung cancer	Lung cancer	General Drugs	MIMS HK
		Hodgkin's disease, Non-Hodgkin's Lymphoma	Lymphatic system cancer	General Drugs	MIMS HK
135	ZANUBRUTINIB	Waldenstrom's macroglobulinaemia (WM) 華氏巨球蛋白血症	Lymphatic system cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
		Monotherapy for the treatment of adult patients with Waldenström's macroglobulinaemia (WM) who have received at least one prior therapy 作為單一療法，用於曾接受至少一種療法的華氏巨球蛋白血症成年患者	Lymphatic system cancer	Self-financed item With Safety Net (CCF Medical Assistance	HA Website
		Chronic lymphocytic leukaemia (CLL)	Blood and bone marrow cancer	Self-financed item Without Safety Net	HA Website

*Drug Formulary Category refers to the Hospital Authority "Drug Formulary" categories *藥物名冊分類 是指醫院管理局《藥物名冊》分類	
General Drugs 通用藥物	These are drugs with well-established indications and cost- effectiveness which are available for general use as indicated by patients with relevant clinical conditions and provided at standard fees and charges in public hospitals and clinics. 經證實對病人有關臨床情況適用和有效，並可供一般使用的藥物。公立醫院和診所提供這類藥物時，會收取標準費用。
Special Drugs 專用藥物	These are drugs used under specific clinical conditions with specific specialist authorisation. Special drugs are provided at standard fees and charges in public hospitals and clinics when prescribed under specific clinical conditions. Patients who do not meet the specified clinical conditions but choose to use Special drugs are required to pay for the drugs. 在特定臨床應用下經專科醫生特別授權使用的藥物。如這類藥物是在特定的臨床應用下處方，公立醫院和診所會收取標準費用。如個別病人在特定臨床應用以外選擇使用專用藥物，便需自行支付藥物的費用。
Self-financed Items (SFIs) with Safety Net 獲安全網資助的自費購買藥物 （自費藥物）	These are drugs which are proven to be of significant clinical benefits but are very expensive for HA to provide as part of its standard services. These drugs are not covered by the standard fees and charges in public hospitals and clinics. Patients who require these drugs and can afford the costs have to purchase the drugs at their own expense. A safety net is provided through relevant funds to subsidize the drug expenses of patients who have financial difficulties. 經證實有顯著療效，但超出醫管局一般資助服務範圍所能提供的非常昂貴藥物。這些藥物不屬公立醫院和診所標準收費提供的項目。需要使用這些藥物而有能力負擔費用的病人須自費購買。然而，相關基金會為需要這些藥物而經濟上有困難的病人提供安全網。

SFIs without Safety Net 不獲安全網資助的自費藥物	These include drugs with preliminary medical evidence only, drugs with marginal benefits over available alternatives but at significant higher costs, and lifestyle drugs (e.g. anti-obesity drugs). These drugs are not provided as part of HA's standard services nor covered by the standard fees and charges in public hospitals and clinics. Patients who choose to use these drugs must purchase them at their own expense. 僅經初步醫療驗證的藥物、與其他替代藥物相比僅具邊緣效益，但成本明顯昂貴的藥物，以及生活方式藥物(例如減肥藥)。這些藥物並不會包括在標準收費範圍內，病人需自費購買。
---	--

(Source of information 資料來源： <https://www.ha.org.hk/hadf/en-us/Drug-Formulary-Management.html>)